Role of Urokinase Plasminogen Activator and Plasminogen Activator Inhibitor MRNA Expression As Prognostic Factors in Molecular Subtypes of Breast Cancer

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2014 Dec 16

PMID 25506225

Citations 12

Authors

Isabell Witzel

Karin Milde-Langosch

Marcus Schmidt

Thomas Karn

Sven Becker

Ralph Wirtz

Achim Rody

Elena Laakmann

Dina Schutze

Fritz Janicke

Volkmar Muller

Affiliations

Soon will be listed here.

Abstract

Background: Protein levels of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) determined by enzyme-linked immunosorbent assay from fresh-frozen tumor tissue have been evaluated as prognostic factors in prospectively randomized trials in breast cancer. However, the role of uPA and PAI-1 in the context of breast cancer subtypes and for mRNA expression of these factors is less clear.

Methods: We evaluated uPA and PAI-1 mRNA expression using the Affymetrix HG-U 133A array within molecular subgroups of breast cancer in cohorts of patients with systemic treatment (cohort A, n=362) and without systemic treatment (cohort B, n=200). We validated mRNA expression in a cohort of HER2-positive breast cancer patients (cohort C, n=290). Luminal, triple-negative, and HER2-positive subcohorts were defined by ESR1 and ERBB2 mRNA expression using predefined cutoffs.

Results: In the entire cohort A, elevated PAI-1 but not uPA mRNA expression was associated with shorter disease-free survival (P=0.007 for PAI and 0.069 for uPA). Regarding different molecular subgroups, 67% (n=244) of tumors were luminal, 14% (n=49) were HER2-positive, and 19% (n=69) were triple-negative. Elevated PAI-1 mRNA expression was associated with shorter disease-free survival only in the HER2-positive subgroup (P=0.031). The same disease-free survival results were found for uPA in HER2-positive patients (P=0.011). In contrast, no association between either marker and survival was observed in the luminal or triple-negative subgroups. In the HER2-positive validation cohort C, elevated uPA and PAI-1 mRNA expression also showed strong associations with shorter disease-free survival (P=0.014 for PAI-1, P<0.001 for uPA).

Conclusion: In this study, the prognostic impact of uPA and PAI-1 expression was mainly observed in patients with HER2-positive tumors.

Citing Articles

Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells.

Poskus M, McDonald J, Laird M, Li R, Norcoss K, Zervantonakis I Cell Mol Bioeng. 2024; 17(5):491-506.

PMID: 39513002 PMC: 11538110. DOI: 10.1007/s12195-024-00823-0.

Exploring the multifaceted role of obesity in breast cancer progression.

Kakkat S, Suman P, Turbat-Herrera E, Singh S, Chakroborty D, Sarkar C Front Cell Dev Biol. 2024; 12():1408844.

PMID: 39040042 PMC: 11260727. DOI: 10.3389/fcell.2024.1408844.

The relation between excess adiposity and breast cancer in women: Clinical implications and management.

Hurtado M, Tama E, DAndre S, Shufelt C Crit Rev Oncol Hematol. 2023; 193:104213.

PMID: 38008197 PMC: 10843740. DOI: 10.1016/j.critrevonc.2023.104213.

SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis by sponging miR-942-5p and activating PI3K/Akt signaling.

Zhang W, Yang S, Chen D, Yuwen D, Zhang J, Wei X Cell Mol Life Sci. 2022; 79(1):59.

PMID: 34997317 PMC: 11072091. DOI: 10.1007/s00018-021-04120-1.

The Importance of Breast Adipose Tissue in Breast Cancer.

Kothari C, Diorio C, Durocher F Int J Mol Sci. 2020; 21(16).

PMID: 32796696 PMC: 7460846. DOI: 10.3390/ijms21165760.

References

Witzel I, Milde-Langosch K, Wirtz R, Roth C, Ihnen M, Mahner S . Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol. 2010; 136(11):1709-18. DOI: 10.1007/s00432-010-0829-4. View

Sternlicht M, Dunning A, Moore D, Pharoah P, Ginzinger D, Chin K . Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 2006; 15(11):2107-14. PMC: 2731792. DOI: 10.1158/1055-9965.EPI-06-0351. View

Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A . Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer. 2006; 6:216. PMC: 1564186. DOI: 10.1186/1471-2407-6-216. View

Biermann J, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep F . Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med. 2008; 21(2):251-9. View

Milburn M, Rosman M, Mylander C, Tafra L . Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?. Breast J. 2013; 19(4):357-64. DOI: 10.1111/tbj.12126. View

Castello R, Landete J, Espana F, Vazquez C, Fuster C, Almenar S . Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb Res. 2007; 120(5):753-62. DOI: 10.1016/j.thromres.2006.12.016. View

Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H . The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68(13):5405-13. DOI: 10.1158/0008-5472.CAN-07-5206. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Kelly C, Krishnamurthy S, Bianchini G, Litton J, Gonzalez-Angulo A, Hortobagyi G . Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010; 116(22):5161-7. DOI: 10.1002/cncr.25269. View

10.

Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S . uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem. 2008; 45:31-45. DOI: 10.1016/s0065-2423(07)00002-9. View

11.

Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M . Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013; 49(8):1825-35. DOI: 10.1016/j.ejca.2013.01.007. View

12.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

13.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

14.

Look M, van Putten W, Duffy M, Harbeck N, Christensen I, Thomssen C . Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002; 94(2):116-28. DOI: 10.1093/jnci/94.2.116. View

15.

Hanker L, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C . Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Res Treat. 2012; 137(2):407-16. DOI: 10.1007/s10549-012-2356-2. View

16.

Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B . Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res. 2001; 7(8):2448-57. View

17.

Harbeck N, Ross J, Yurdseven S, Dettmar P, Polcher M, Kuhn W . HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol. 1999; 14(4):663-71. DOI: 10.3892/ijo.14.4.663. View

18.

Karn T, Metzler D, Ruckhaberle E, Hanker L, Gatje R, Solbach C . Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat. 2009; 120(3):567-79. DOI: 10.1007/s10549-009-0416-z. View

19.

Zemzoum I, Kates R, Ross J, Dettmar P, Dutta M, Henrichs C . Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 2003; 21(6):1022-8. DOI: 10.1200/JCO.2003.04.170. View

20.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View